Abstract 448P
Background
Chemotherapy efficacy depends on relative dose intensity (RDI) and an RDI <85% is associated with unfavourable overall survival. Clinicopathological characteristics have been observed as risk factors of reduced RDI. The pro-inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP), which also serve as biomarkers of aging, have been reported to associate with RDI. We aimed to determine whether these parameters have influence on RDI in the local breast cancer (BC) patients.
Methods
This cross-sectional study recruited 172 women with stage I-IV BC receiving first-line chemotherapy between July 2018-March 2022. Sociodemographic, clinicopathological, and treatment data and peripheral blood samples were collected prior to chemotherapy. IL-6 and CRP levels were analyzed using quantitative ELISA. Dose reductions and delays were captured and utilized to calculate the patient’s RDI. Multivariable logistic regression analysis was performed to determine the association between pre-chemotherapy parameters and RDI <85%.
Results
Mean age was 52 years (range 32-78). The average RDI for all patients was 93% and an RDI <85% occurred in 23 (13.4%) patients. Mean IL-6 level was 1.12 pg/ml (range 0.0–27.7) and mean CRP was 10.82 μg/ml (range 0.0–151.7). Factors associated with reduced RDI were diabetes mellitus comorbidity (OR 5.13, 95% CI 1.38–19.03; p =0.015), triple-negative tumours (OR 4.17, 95% CI 1.09–15.89; p =0.037), palliative treatment setting (OR 3.75, 95% CI 1.12–12.62, p =0.032), and IL-6 serum level >0.485 pg/ml (OR 3.46, 95% CI 1.05–11.37; p =0.041).
Conclusions
The presence of diabetes mellitus comorbidity, triple-negative tumours, palliative treatment intention, and IL-6 serum level >0.485 pg/ml are associated with reduced RDI. Further investigation is warranted to confirm the association between biomarker of aging and chemotherapy delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, The Ministry of Education, Culture, Research, and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract